CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
For patients with refractory acute leukemia, allogeneic stem cell transplantation is the only
curative therapy. Only 20% of patients may achieve long-term survival mostly due to relapse
or nor-relapse mortality (NRM). In previous study, we demonstrated that intensive leukemia
debulking chemotherapy FLAG-IDA sequential with Flu-BU conditioning is feasible with ~40%
long-term survival. In the study, we further modified the chemotherapy with cladribine
replacing fludarabine aiming a more potent anti-leukemia effect. Meanwhile, we reduce the
dose of busulfan for patients with poor performance status and age over 45 aim to reduce the
NRM. All patients will also receive post-transplantation maintenance therapy with low-dose
decitabine to prevent relapse.